TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy.
about
Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7Endothelial cell phenotypes in the rheumatoid synovium: activated, angiogenic, apoptotic and leakyAnti-TNF-alpha therapy as a clinical intervention for periprosthetic osteolysis.Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alphaUpdate on D2E7: a fully human anti-tumour necrosis factor alpha monoclonal antibody.Antibody-based delivery of IL4 to the neovasculature cures mice with arthritis.Resolution of inflammation in murine autoimmune arthritis is disrupted by cyclooxygenase-2 inhibition and restored by prostaglandin E2-mediated lipoxin A4 production.The efficacy and safety of certolizumab pegol (CZP) in the treatment of active rheumatoid arthritis (RA): a meta-analysis from nine randomized controlled trials.Systems approaches to human autoimmune diseases.Murine analogues of etanercept and of F8-IL10 inhibit the progression of collagen-induced arthritis in the mouse.Inflammatory 'double hit' model of temporomandibular joint disorder with elevated CCL2, CXCL9, CXCL10, RANTES and behavioural hypersensitivity in TNFR1/R2-/- mice.Understanding Human Autoimmunity and Autoinflammation Through Transcriptomics.Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.New strategies for treatment of pulmonary fibrosis.Macrophage-derived, macrophage migration inhibitory factor (MIF) is necessary to induce disease in the K/BxN serum-induced model of arthritis.Model answers: Rational application of murine models in arthritis research.
P2860
Q24675216-FD3D1B10-CCD8-46E6-BE78-841604678E21Q24793680-1BFB0728-D4B0-48DC-AEB0-68335BBFC102Q24806847-A1A758C5-2AC9-4E2F-87ED-93E7B23F9782Q33618096-CAF857AF-D1E5-4B36-A045-9113B0277EA7Q34071283-104FEEB4-FB45-4AD7-86FF-BAD2F3B6F0DCQ34083054-AC9EFBB1-6952-48FE-B331-791BCB3229B4Q34546662-F1A2880C-7FCD-4EB0-AFC2-692CB5EC680BQ34769757-C91E39FB-822B-44CD-89E2-24B63FF3AD9FQ37584747-C11FF77B-D27C-4514-B391-5BD1DF0DDCC8Q37690616-BE1B5BE9-3AF9-4B91-A9EC-BE9DE231BFB2Q38894635-3A090721-D2A1-49B3-A1FA-210A1034C55BQ38988559-CFB11613-6D92-4E24-8441-D748D67C92DBQ38993250-AC2F89FE-255D-42CC-B87A-01016CA970EFQ40547106-77D803BB-3337-475D-92B2-CB9607344296Q41837807-BC18FD05-2BEA-42D7-8FAF-137AF50A3771Q47807913-481DEB49-2722-4347-8F0E-DA28EDC0FB36
P2860
TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy.
@en
type
label
TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy.
@en
prefLabel
TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy.
@en
P2093
P1476
TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy.
@en
P2093
F M Brennan
M Feldmann
R Williams
P304
P478
11 Suppl 8
P577
1993-03-01T00:00:00Z